

Introduction & Notes re: MVB Annual Assessment Setting Workbook

MVB Calendar Year 2023

[Note: This is Working Version as of 9/20/2022.]

01. This workbook follows the past naming conventions with each sheet beginning with a letter (i.e., "a." through "d."), and each cell within each sheet being identified by a 2-digit row number (e.g., "01.") and column letter (e.g., "A"). So, to facilitate reference while collaborating via conference phone, users can refer to any single number, for example the new assessment rate, by a combination of the above. For that key number, the new monthly assessment rate, the reference is "a.27.C".
02. Since the first measurement period is for the month of January and assessments are due forty-five (45) days after the end of each quarter, the first assessment payment with the new rate will be May 15, 2023 for the months of Jan-Mar, 2023.
03. The primary spreadsheet for the work is the assessment calculation worksheet, worksheet a. The other sheets are intended to be reference or to develop background data in specific areas for the work. Key data for developing the primary funding target is on spreadsheet b. which contains data supplied by the Maine CDC for the vaccine funding needs. Key numbers from a subsidiary sheet rolled into the main assessment sheet generally are shaded in yellow.
04. These spreadsheets have Board controls. This is intended to help users test various assumptions and control points which may be adjusted by the MVB in setting the final new rate. Those cells in which entries normally would be made are shaded in green. For example, a user can adjust utilization assumptions for increases over prior years by entering percent's either by vaccine on sheet b. or overall on sheet a (a.3.D). The vaccine funding target takes the number as adjusted by those two factors and then applies the assumed cost increase (a.4.D). The cost increase is applied for 9/12 of the year since it typically becomes effective as of April 1 each year.
05. Because the first collections of the year (due February 15) will still be at the old rate and based upon covered lives reported for Oct-Dec 2022, this spreadsheet first deducts that quarterly collection and then calculates the new rate based upon what is needed to hit the funding target over the remaining 9 months.
06. It is anticipated that the MVB will, as part of its deliberations and upon considering the input of any public members or others at its meeting(s), adjust the assumptions which guide the assessment level. Of course, the MVB may also determine to adjust the assessment setting process itself or this workbook structure at any time.

Maine Vaccine Board

2023 Calendar Year Assessment Calculation

Column →	A	B	C	D	E
Line ↓	2022		2023		
A. Preliminary Vaccine Cost, Projection Parameters, & Population Estimates					
01.	\$15,140,087		\$13,552,245		State Fiscal Year Vaccine Estimate (from tab b.)
02.	136,487		135,947		Estimate of Covered Lives (Covered Lives tab c.)
03.	\$151,401	1.0%	\$135,522	1.0%	Provision for Vaccine Utilization increase
04.	\$470,213	4.1%	\$369,570	3.6%	Vaccine cost inflation factor (prices change each April 1st)
05.	\$15,761,701		\$14,057,337		¹ Calendar Year Vaccine Funding Estimate
B. Budget Estimates					
06.	\$153,351		\$161,019		³ Servicing Agent Contract for Administrative Services
07.	\$7,350		\$7,500		Audit Fee (Move to paid public auditor)
08.	\$7,500		\$8,500		Bank Fees (adding TD Bank Lockbox including setup expenses)
09.	\$10,500		\$10,500		Legal (services of AG's office only estimated)
10.	\$178,701		\$187,519		Total Operating Costs Projected
C. Financial Carry Forwards					
11.	\$5,940,967		\$9,374,488		Estimated Starting Balance January 1
12.	\$3,800,499	3.0	\$3,280,526	3.00	Amount Retained for Liquidity Reserve - 3.0 months of non flu
13.	\$559,704		\$935,232		Amount Retained for Liquidity Reserve - full annual flu cost
14.	\$1,580,764		\$5,158,729		Carryforward used to reduce current assessment calculation
D. Aggregate Annual Assessment Calculation					
15.	\$15,761,701		\$14,057,337		Costs of Vaccines Provided
16.	\$178,701		\$187,519		Total Operating Costs
17.	\$0		\$0		Other (as approved by board -- see statute section 2.M)
18.	\$15,940,402		\$14,244,855		"Total Costs of the Fund" per statute section 2.M.
19.	\$55,791	0.35%	\$49,857	0.35%	Collection Losses (i.e. assumed "bad debt expense")
20.	-\$102,607		-\$80,039		² Interest Income
21.	-\$1,580,764	-9.9%	-\$5,158,729	-36.2%	(excess) or shortfall of cash from prior operating year
22.	\$557,914	3.50%	\$498,570	3.50%	add reserve up to 10% per statute section 5.A.(3).
23.	\$14,870,737		\$9,554,514		Total Assessments Needed
24.	-\$3,258,905		-\$3,855,292		Projected assessments February 15 at old rate
25.	\$11,611,832		\$5,699,222		Total Assessments Needed at new rate
E. Per Covered Life Assessment Calculation					
26.	\$113.44		\$55.90		Annual Assessment per Covered Life
27.	\$9.45		\$4.66		Monthly Assessment per Covered Life
28.	6.2%		-10.5%		% Change in Vaccine Costs
29.	18.8%		-50.7%		% Change in Assessment
30.			\$4.66		Issued Monthly Assessment per Covered Life
31.			-50.7%		Issued % Change in Assessment
F. Note: Total Assessed as % of Hard Vaccine Costs					
32.	-5.7%		-32.0%		All-in costs % above vaccine costs
G. Indicated Monthly Assessment Level next year apart from reserve / cash changes					
33.	\$10.48		\$10.62		⁴ Preliminary Assessment projection

Notes

- ¹ Maine CDC + per vaccine adjustments + utilization increase with inflation factor.
- ² Used the average of FY20-FY22 Investment Income from audited financials.
- ³ Fixed price contract all inclusive of expenses.
- ⁴ Projection: annual amounts w/ carryforward cash, reserve changes, and 1 more year of inflation & utilization changes.

Maine CDC Vaccine Projection Data

Column →
Line ↓

A B C D E F G H I J K

	Vaccine	Brand Name	NDC	Prior Year Actuals			Federal FY 23 Estimates			Vaccine Funding Target	
				Cost Per Dose	Doses	Cost	Cost Per Dose	Doses	Cost		
01.	DAPTACEL	Sanofi Pastuer	49281-0286-10	\$ 19.20	2,859	\$ 54,893	\$ 19.88	3,221	\$64,033	0%	\$64,033
1.b				\$ 19.88	589	\$ 11,709.32					
02.	PENTACEL	Sanofi Pastuer	49281-0511-05	\$ 63.38	6,948	\$ 440,392.03	\$ 65.77	8,086	\$531,816	0%	\$531,816
2.b				\$ 65.77	1,707	\$ 112,269.39					
03.	QUADRACEL	Sanofi Pastuer	49281-0562-10	\$ 43.35	850	\$ 36,847.50	\$ 44.32	859	\$38,071	0%	\$38,071
3.b				\$ 44.32	69	\$ 3,058.08					
04.			49281-0564-15	\$ -	0	\$ -	\$ -	0	\$38,071	0%	\$0
4.b	IPOL (EIPV)	Sanofi Pastuer	49281-0860-10	\$ 14.06	2,643	\$ 37,160.58	\$ 15.11	3,108	\$46,971	0%	\$46,971
05.				\$ 15.11	419	\$ 6,332.35					
5.b	Menactra (MCV4)	Sanofi Pastuer	49281-0589-05	\$ 100.05	7,301	\$ 730,465.05					
06.				\$ 104.72	1,337	\$ 140,010.64					
	Medquadfi	Sanofi Pastuer	49281-0590-05	\$ 100.05	1,336	\$ 133,666.80	\$ 104.72	12,208	\$1,278,397	0%	\$1,278,397
07.				\$ 104.72	308	\$ 32,253.76					
7.b	ACTHIB (HIB)	Sanofi Pastuer	49281-0545-03	\$ 10.02	3,173	\$ 31,793.46	\$ 10.39	9,028	\$93,801	0%	\$93,801
08.				\$ 10.39	183	\$ 1,901.37					
8.b	ADACEL (Tdap)	Sanofi Pastuer	49281-0400-20	\$ 33.16	1,473	\$ 48,844.68	\$ 34.40	2,465	\$84,786	0%	\$84,786
09.				\$ 34.40	276	\$ 9,493.30					
9.b	TENIVAC	Sanofi Pastuer	49281-0215-15	\$ 21.77	148	\$ 3,221.96	\$ 22.58	279	\$6,300	0%	\$6,300
10.				\$ 22.58	50	\$ 1,129.00					
10.b	TRUMENBA (Menb)	Pfizer	00005-0100-10	\$ 119.93	895	\$ 107,337.35	\$ 125.77	364	\$45,780	0%	\$45,780
11.				\$ 125.77	47	\$ 5,911.19					
11.b	Prevnar 13 (PCV 13)	Pfizer	00005-1971-02	\$ 150.83	15,444	\$ 2,329,419	\$ 158.18	18,834	\$2,979,162	0%	\$2,979,162
11.c				\$ 158.18	4,151	\$ 656,605					
12.	Bexsero (Menb)	GlaxoSmithKline	58160-0976-20	\$ 128.60	1,513	\$ 194,572	\$ 135.00	4,692	\$633,406	0%	\$633,406
12.b				\$ 135.00	591	\$ 79,783					
12.c	MENVEO (MCV4)	GlaxoSmithKline	58160-0955-09	\$ 99.58	1,632	\$ 162,515	\$ 102.55	2,270	\$232,779	0%	\$232,779
13.				\$ 102.55	280	\$ 28,713					
13.b	Infanrix (DTaP)	GlaxoSmithKline	58160-0810-52	\$ 19.84	960	\$ 19,046	\$ 20.37	1,144	\$23,301	0%	\$23,301
13.c				\$ 20.37	265	\$ 5,398					
14.	Pediarix (DTaP/Hep B/IPV)	GlaxoSmithKline	58160-0811-52	\$ 62.49	2,857	\$ 178,534	\$ 62.49	3,104	\$193,975	0%	\$193,975
14.b				\$ 62.49	465	\$ 29,058					
15.	Kinrix (DTaP/IPV)	GlaxoSmithKline	58160-0812-52	\$ 43.64	2,990	\$ 130,484	\$ 45.27	3,735	\$169,080	0%	\$169,080
15.b				\$ 45.27	1,008	\$ 45,631					
15.c	Havrix (Hep A)	GlaxoSmithKline	58160-0825-52	\$ 21.72	7,738	\$ 168,069	\$ 22.35	14,498	\$324,074	0%	\$324,074
16.				\$ 22.35	2,232	\$ 49,885					
16.b	Engerix-B (Hep B)	GlaxoSmithKline	58160-0820-52	\$ 15.67	3,240	\$ 50,771	\$ 16.27	11,316	\$184,111	0%	\$184,111
16.c				\$ 16.27	1,024	\$ 16,660					\$0

Maine CDC Vaccine Projection Data

17.	Rotarix (Rota)	GlaxoSmithKline	58160-0854-52	\$ 99.44	2,896	\$ 287,978	\$ 102.40	2,705	\$277,003	0%	\$277,003
17.b				\$ 102.40	642	\$ 65,741					
18.	Boostrix (TDaP)	GlaxoSmithKline	58160-0842-52	\$ 34.07	4,676	\$ 159,311	\$ 35.02	7,975	\$279,300	0%	\$279,300
18.b				\$ 35.02	982	\$ 34,390					
19.	HIBERIX	GlaxoSmithKline	58160-0818-11	\$ 9.62	23	\$ 221	\$ 10.10	62	\$626	0%	\$626
19.b				\$ 10.11	0	\$ -					
19.c	VAQTA (Hep A)	Merck Sharp & Dohme Corp.	00006-4095-02	\$ 21.40	1,721	\$ 36,829	\$ 22.64	3,276	\$74,169	0%	\$74,169
20.				\$ 22.64	532	\$ 12,044					
20.b	RECOMBIVAX (Hep B)	Merck Sharp & Dohme Corp.	00006-4981-00	\$ 13.00	2,172	\$ 28,236	\$ 13.55	7,417	\$100,500	0%	\$100,500
21.				\$ 13.55	623	\$ 8,442					
21.b	PedvaxHib (Hib)	Merck Sharp & Dohme Corp.	00006-4897-00	\$ 13.79	2,780	\$ 38,336	\$ 14.82	8,616	\$127,689	0%	\$127,689
22.				\$ 14.82	423	\$ 6,269					
22.b	Gardasil (HPV9)	Merck Sharp & Dohme Corp.	00006-4121-02	\$ 196.32	8,815	\$ 1,730,561	\$ 208.05	12,000	\$2,496,600	0%	\$2,496,600
23.				\$ 208.05	1,921	\$ 399,664					
23.b	Vaxelis	Merck Sharp & Dohme Corp.	63361-0243-15	\$ 91.59	3,327	\$ 304,720	\$ 95.07	4,268	\$405,759	0%	\$405,759
24.				\$ 95.07	1,242	\$ 118,077					
24.b	ROTATEQ (Rota)	Merck Sharp & Dohme Corp.	00006-4047-41	\$ 74.73	6,795	\$ 507,790	\$ 76.95	6,519	\$501,637	0%	\$501,637
24.c				\$ 76.95	1,732	\$ 133,277					
24.d	MMR II	Merck Sharp & Dohme Corp.	00006-4681-00	\$ 22.11	4,679	\$ 103,453	\$ 23.67	5,634	\$133,357	0%	\$133,357
25.				\$ 23.67	1,286	\$ 30,440					
26.	Proquad (MMRV)	Merck Sharp & Dohme Corp.	00006-4171-00	\$ 144.63	3,560	\$ 514,883	\$ 153.51	4,817	\$739,443	0%	\$739,443
26.b				\$ 153.51	1,540	\$ 236,405					
27.	Pneumovax23 (Pedi)	Merck Sharp & Dohme Corp.	00006-4837-03	\$ 62.08	302	\$ 18,748	\$ 65.80	130	\$8,554	0%	\$8,554
27.b				\$ 65.80	17	\$ 1,119					
28.	Varivax	Merck Sharp & Dohme Corp.	00006-4827-00	\$ 115.77	3,790	\$ 438,768	\$ 122.67	4,836	\$593,232	0%	\$593,232
28.b				\$ 122.67	1,330	\$ 163,151					
29.	Fluzone PF 0.5ml (6mth+)	Sanofi Pasteur	49281-0422-50	\$ 14.25	24,000	\$ 342,000	\$ 14.25	24,000	\$342,000	0%	\$342,000
29.b	FluMist Sprayer, 10-pack (2-18)	Astra Zeneca	66019-0309-10	\$ 18.88	3,500	\$ 66,080	\$ 18.88	3,500	\$66,080	0%	\$66,080
30.	Flulaval PF 0.5ml (6mth+)	GlaxoSmithKline	19515-0808-52	\$ 14.66	32,500	\$ 476,450	\$ 14.66	32,500	\$476,450	0%	\$476,450
31.				\$ -		\$ -					
32.				\$ -	0	\$ -				\$38,071	
33.				\$ -	0	\$ -					
34.						\$ 12,357,218			\$13,590,316	\$58.58	\$13,552,245
35.	TOTAL				196,807	\$ 12,357,218		227,466	\$13,590,316		\$13,552,245
36.										Adjusted for overall utilization increase	\$13,687,767
37.										Adjusted for price increase	\$14,057,337

Maine Vaccine Board
Estimated Covered Lives
2023 Calendar Year Assessment Calculation

Covered lives reported to KV for historical quarters:

	<u>Quarter</u>	<u>Monthly Average</u>	<u>Quarterly Change</u>	<u>12 Month Average</u>	
				<u>Lives</u>	<u>R12 Trend</u>
Q1 ending 9/30/2020	409,412	136,471	-2.43%	138,817	-0.62%
Q2 ending 12/31/2020	410,327	136,776	0.22%	138,419	-0.75%
Q3 ending 3/31/2021	411,052	137,017	0.18%	137,533	-1.31%
Q4 ending 6/30/2021	407,050	135,683	-0.97%	136,487	-2.07%
Q1 ending 9/30/2021	407,470	135,823	0.10%	136,325	-1.80%
Q2 ending 12/31/2021	406,978	135,659	-0.12%	136,046	-1.71%
Q3 ending 3/31/2022	409,821	136,607	0.70%	135,943	-1.16%
Q4 ending 6/30/2022	407,090	135,697	-0.67%	135,947	-0.40%
Best Current Estimate				135,947	